“…The first of the two methods is based on allowing the healthy cells to take on a cancer cell feature, in analogy to the way a person in love adopts the personality traits of the object of his/her affection. This first approach can be said to have been motivated by the path taken on by Yamanaka et al, whose Nobel Prize-awarded research [27] was on converting the phenotype of differentiated cells back to a pluripotent state when the rest of the stem cell research community rushed to find means of differentiating stem cells into specific lineages [28]. Similarly, here, in times when the dominant course of action in the field of genetic engineering for cancer mitigation, the immunotherapeutic efforts notwithstanding, is still to modify the cancer cell by introducing specific therapeutic factors to it-be it by means of extracellular vesicles, small interfering RNAs (siRNAs), CRISPR/Cas9 gene editing, controlled delivery of chemotherapeutic drugs or other biomolecules to shut down the cell metabolism-the healthy cells adjacent to the cancer cells will be altered in their makeup in such a way that they begin to resemble the latter cells more, not less.…”